SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Crown J,O'Leary M. The taxanes: an update. Lancet. 2000; 355: 11761178.
  • 2
    Chevallier B,Fumoleau P,Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995; 13: 314322.
  • 3
    Fossella FV,Lee JS,Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994; 12: 12381244.
  • 4
    Francis P,Schneider J,Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994; 12: 23012308.
  • 5
    Hajek R,Vorlicek J,Slavik M. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies. Minireview. Neoplasma. 1996; 43: 141154.
  • 6
    Childress J,Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003; 26: 435436.
  • 7
    Minisini AM,Tosti A,Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003; 14: 333337.
  • 8
    Nagore E,Insa A,Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000; 1: 225234.
  • 9
    Winther D,Saunte DM,Knap M,Haahr V,Jensen AB. Nail changes due to docetaxel—a neglected side effect and nuisance for the patient. Support Care Cancer. 2007; 15: 11911197.
  • 10
    Vassallo C,Brazzelli V,Ardigo M,Borroni G. The irreplaceable image: nails changes in onco-hematologic patients. Haematologica. 2001; 86: 334336.
  • 11
    Correia O,Azevedo C,Pinto Ferreira E,Braga Cruz F,Polonia J. Nail changes secondary to docetaxel (Taxotere). Dermatology. 1999; 198: 288290.
  • 12
    Scotte F,Tourani JM,Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005; 23: 44244429.
  • 13
    Spazzapan S,Crivellari D,Lombardi D, et al. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol. 2002; 20: 44044405, author reply 4405.
  • 14
    Engels FK,Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer. 2005; 41: 11171126.
  • 15
    Kuroi K,Bando H,Saji S,Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer. 2003; 10: 1014.
  • 16
    Robert C,Faivre S,Raymond E,Armand JP,Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005; 143: 313314.
  • 17
    Katsimbri P,Bamias A,Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer. 2000; 36: 766771.
  • 18
    Ridderheim M,Bjurberg M,Gustavsson A. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer. 2003; 11: 371377.
  • 19
    Mahood DJ,Dose AM,Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991; 9: 449452.
  • 20
    Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995; 73: 333346.
  • 21
    Spadaro P,Maisano R,Mare M. Is there any correlation between decreased serum vascular endothelial growth factor (sVEGF) levels and nail toxicity in responsive metastatic breast cancer (MBC) patients treated with weekly docetaxel? Preliminary data of a phase II study. Proc Am Soc Clin Oncol. 2002. Abstract 1952.
  • 22
    Wasner G,Hilpert F,Schattschneider J,Binder A,Pfisterer J,Baron R. Docetaxel-induced nail changes—a neurogenic mechanism: a case report. J Neurooncol. 2002; 58: 167174.
  • 23
    De Giorgi U,Rosti G,Monti M,Frassineti GL,Marangolo M. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL). Ann Oncol. 2003; 14: 15881589.